Dermatologica Helvetica 4 / 2011 - Effet placebo - Derma.ch
←
→
Transkription von Seiteninhalten
Wenn Ihr Browser die Seite nicht korrekt rendert, bitte, lesen Sie den Inhalt der Seite unten
Dermatologica
Helvetica
Placebowirkung Effet placebo
Radiotherapie USZ Radiothérapie
Fokus Psoriasis Focus psoriasis
Vorprogramm Pré-programme
93. Jahresversammlung 93ème Réunion Annuelle
der SGDV de la SSDV
Dieses Heft wurde für die Fortbildung der Schweizer
Dermatologen dank einer Hilfe der folgenden Firma
realisiert:
Ce numéro à été réalisé grâce à une aide pour la forma-
tion continue des dermatologues suisses de la firme:
4 / 2011
Die Erweiterung der
Haarausfall-Therapie
für die systemische und topische Behandlung
NEU
Alocapil®
Z: Finasterid Filmtabletten à 1mg. I: Leichte bis mittelschwere androgenetische Alopezie bei Männern. D: 1 x 1 Tablette täglich während mind. 3 Monaten oder mehr. KI: Frauen, Kinder, Schwangerschaft, Alopezie
anderer Genese, Überempfindlichkeit gegen einen Inhaltsstoff. VM: Einfluss auf PSA-Wert, sehr seltene Fälle von Brustkrebs bekannt. Zerdrückte oder zerbrochene Tabletten sollen von Frauen im gebärfähigen Alter
nicht gehandhabt werden. IA: Substrat von CYP3A4, kein Hinweis auf klinisch relevante Interaktionen. UAW: Häufig: verminderte Libido, Erektionsstörung. SS/ST: Schwangerschaft: kontraindiziert; Stillzeit: nicht indiziert.
P: Filmtabletten, 28 und 98. Liste B. Weiterführende Informationen entnehmen Sie dem Arzneimittel-Kompendium der Schweiz. 1110
Neocapil®5%
Z: Minoxidil 50mg/ml Lösung. I: Alopecia androgenetica bei Männern, bei Frauen auf ärztliche Verschreibung. D: Erw. >18 J.: Äusserlich 1ml (entspricht 10 Sprühstössen) 2x tgl. während mind. 4 Monaten auf die gesunde,
trockene Kopfhaut auftragen. Nicht auf andere Körperstellen auftragen. Max. 2ml/Tag. KI: Bekannte Überempfindlichkeit gegen einen Inhaltsstoff. VM: Vorsicht bei kardiovaskulären Erkrankungen, Arrhythmien, bei ver-
sehentlicher Einnahme, bei Anzeichen systemischer Wirkung durch erhöhte Resorption. Augen-und Schleimhautkontakt vermeiden, Spraydämpfe nicht einatmen. Nicht mit anderen Topika zusammen verwenden. Graues
Haar und Schwimmen in chemisch aufbereitetem Wasser (Veränderung Haarfarbe, Haarstruktur). Pat. 65J. IA: Antihypertonika, Arzneimittel gegen erektile Dysfunktion, Betablocker, andere Topika und Mittel,
welche die Hautresorption verstärken. UAW: Häufig: Ekzematische Rektionen, allergische Kontaktdermatitis, Haarausfall und Alopezie, Hypertrichose inkl. Wachstum von Gesichtshaaren bei Frauen, lokale Erytheme,
Pruritus, trockene, schuppende Haut. SS/ST: Keine kontrollierten Studien vorhanden, während der Schwangerschaft / Stillzeit nicht anwenden. P: Flasche à 50ml mit Sprühkopf und Aufsatz mit verlängerter Spitze. Liste C.
Weiterführende Informationen entnehmen Sie dem Arzneimittel-Kompendium der Schweiz. 0910/060111
Spirig Pharma AG, CH-4622 Egerkingen, www.spirig.ch Innovation for skin and health
Sommaire
RUBRIKEN DER DERMATOLOGICA HELVETICA 4 Journal Club
RUBRIQUES DE DERMATOLOGICA HELVETICA
8 Fokus – Focus
Weiterbildung
Formation continue 11 SGDV - SSDV
Redaktionsbüro / Bureau éditorial
20 Terminologie
22 et 26 Reports
J.-H. Saurat Chefredaktor
Editeur en chef 30 News
M. Harms Stv. Chefredaktorin
Editeur en chef adjointe 31 Quiz
A.A. Navarini Assoziierter Redaktor
Editeur associé
A.M. Skaria Redaktor Westschweiz
Editeur député pour la Suisse
romande
T. Hofer Redaktor Deutschschweiz
Editeur député pour la Suisse
alémanique
C. Mainetti Redaktoren Tessin
F. Pelloni Editeurs députés pour le Tessin
e-mail : derm.helv@bluewin.ch
Journal-Klub / Journal-Club
Fokus / Focus
J.-H. Saurat Redaktionsbüro / Bureau éditorial
derm.helv@bluewin.ch
Klinische Fälle / Cas cliniques / Report
Universitätskliniken und praktizierende Ärzte
Les cliniques universitaires et les praticiens
Fragen und Antworten / Questions et réponses Für den Inhalt ausserhalb des redaktionellen Teils (insbesondere Anzeigen, Industrieinformationen,
A.-A. Ramelet, Lausanne Pressezitate und Kongressinformationen) übernehmen Redaktion und Verlag keine Gewähr. Eine
aaramelet@hin.ch
Markenbezeichnung kann warenzeichenrechtlich geschützt sein, auch wenn bei ihrer Verwendung
in dieser Zeitschrift das Zeichen® oder ein anderer Hinweis auf etwa bestehende Schutzrechte fehlen
Neues aus dem Fachgebiet sollten.
Nouvelles professionnelles
L’éditeur et la rédaction déclinent toute responsabilité concernant le contenu non rédactionel du pé-
Forum des Präsidenten der SGDV / riodique (en particulier les annonces, les informations émanant de l’industrie, les citations tirées de la
Tribune du Président de la SSDV presse et les informations issues de congrès). Une marque déposée peut jouir d’une protection légale
J.-P. Grillet même si elle est mentionée dans le périodique sans le symbole ® ou toute autre marque signalant, le
jeanpierre.grillet@hin.ch
cas échéant, une telle protection juridique.
Neues aus der SGDV / Nouvelles de la SSDV
M. Pongratz Dosierungsangaben von Medikamenten:
e-mail: sgdv-ssdv@hin.ch
Neues aus den Kliniken / Nouvelles des cliniques Autoren und Verlag haben alle Anstrengungen unternommen, um sicherzustellen, dass Auswahl und
Klinikdirektoren / Les directeurs des cliniques Dosierungsangaben von Medikamenten im vorliegenden Text mit den aktuellen Vorschriften und
der Praxis übereinstimmen. Trotzdem muss der Leser im Hinblick auf den Stand der Forschung, Än-
Neues aus den kantonalen Fachgesellschaften /
Nouvelles des Sociétés cantonales de la spécialité derungen staatlicher Gesetzgebungen und den unterbrochenen Fluss neuer Forschungsergeenisse
Präsidenten der Gesellschaften / Les présidents des sociétés bezüglich Medikamentenwirkung und -nebenwirkungen darauf aufmerksam gemacht werden, dass
unbedingt bei jedem Medikament der Packungsprospekt konsultiert werden muss, um mögliche
Ankündigungen (Kongresse/Kolloquien) und Berichte /
Annonces (congrès/colloques) et Bureau éditorial
Änderungen im Hinblick auf Indikation und Dosis nicht zu übersehen. Gleiches gilt für spezielle War-
derm.helv@bluewin.ch nungen und Vorsichtsmassnahmen. Ganz besonders gilt dieser Hinweis für empfohlene neue und/
oder nur selten gebrauchte Wirkstoffe.
Freies Forum / Tribune libre Alle Rechte vorbehalten. Ohne schriftliche Genehmigung des Verlags dürfen diese Publikation oder
Redaktionsbüro / Bureau éditorial
derm.helv@bluewin.ch Teile daraus nicht in andere Sprachen übersetzt oder in irgendeiner Form mit mechanischen oder
elektronischen Mitteln (einschliesslich Fotokopie, Tonaufnahme und Mikrokopie) reproduziert oder
Humor / Billet d’humour et d’humeur auf einem Datenträger oder einem Computersystem gespeichert werden.
J.P. Grillet
derm.helv@bluewin.ch
Posologie des médicaments:
Neues aus der Industrie / Nouvelles de l’industrie
Redaktionsbüro / Bureau éditorial Les auteurs et l’éditeur ont tout mis en œuvre pour s’assurer que le choix des médicaments et la
derm.helv@bluewin.ch
posologie préconisés dans ce texte soient conformes aux recommandations et à la pratique au mo-
Druck / Impression ment de la publication. Cependant, compte tenu des recherches en cours, des changements dans
Atar Roto Presse SA, Vernier les législations et de l’afflux constant de données nouvelles concernant la thérapie médicamenteuse
et l’effet des médicaments, il est vivement recommandé au lecteur de vérifier sur la notice jointe à
ISSN : 1420-2360
chaque emballage si aucune modification n’est intervenue dans la posologie et si aucune nouvelle
contre-indication ou précaution à prendre n’a été signalée. Cela est particulièrement important lors-
que l’agent recommandé est nouveau ou peu employé. Tous droits de reproduction, même partielle,
ANZEIGENREGIE / RéGIE DES ANNONCES sous n’importe quelle forme, strictement réservés.
Carine HERRERAS
Tél : +41 79 667 32 48
Fax: +41 22 372 94 95
E-mail : derm.helv@bluewin.ch 3
Effect of Direct-to-Consumer Genomewide Pro- Results: From a cohort of 3639 enrolled subjects,
filing to Assess Disease Risk 2037 completed follow-up. Primary analyses
showed no significant differences between base-
Bloss CS, Schork NJ, Topol EJ line and follow-up in anxiety symptoms (P = 0.80),
Scripps Translational Science Institute, La Jolla, dietary fat intake (P = 0.89), or exercise behavior
USA (P = 0.61). Secondary analyses revealed that test-
related distress was positively correlated with the
New England Journal of Medicine 2011, 346:6 average estimated lifetime risk among all the as-
sessed conditions (β = 0.117, P
Une source pure de soins doux
INNOVATION 2011
Triple action
• Pour les peaux à imperfections sévères
• Soin de relais1
Après des traitements dermatologiques contre l'acné
En cas d’acné tardive
• Prévention des cicatrices d'acné2
Acide glycolique 6% • Rétinaldéhyde® 0,1%
®
Efectiose 0,1%
Parfait pour vos patients :
• Favorise l’élimination des imperfections
(effet peeling)
• Lisse la peau
• Empêche la prolifération des bactéries
• Apaise les inflammations de la peau
1 Etude d’utilisation internationale 2011 (Suisse, 70 patients), résultats provisoires
2 Phase III Etude clinique Pierre Fabre, 2009
22nd
World Congress of
Dermatology
Seoul 2011
Autoimmune Skin Inflammation is Dependent different anatomic locations. In addition, 1 im-
on Plasmacytoid Dendritic Cell Activation by munosuppressed patient suffering from acquired
Nucleic Acids via TLR7 and TLR9 EV harbored MCPyV DNA in 2 common warts. In
contrast, 7 normal skin samples tested negative
Guiducci C, Tripodo C, Gong M, Sangaletti S, Colombo for MCPyV DNA. Only 2 out of 24 carcinomas in
MP, Coffman RL, Barrat FJ situ (8.3%) and 2 out of 30 common warts (6.7%)
Dynavax Technologies Corporation, Berkeley USA from immunocompetent individuals were positive
for MCPyV DNA. Conclusions: The strong associa-
Journal of Experimental Medicine 2010, 207(13): tion of EV-associated skin neoplasms with MCPyV
2931 suggests a unique susceptibility of EV patients to
infections with MCPyV. Both MCPyV and EV-HPV
Recognition of endogenous DNA and RNA by cells may act as synergistic oncogenic cofactors in the
expressing TLR7 and TLR9 is an important contrib- development of EV-associated skin neoplasms.
utor to the pathogenesis of systemic lupus erythe-
matosus and has been suggested to contribute to
cutaneous lupus and to a group of related inflam-
matory skin diseases termed interface dermatitis.
We have developed a mouse model of TLR7- and The Relationship between Neurological Disease
TLR9-dependent skin inflammation using tape and Bullous Pemphigoid: A Population-Based
stripping. In normal mice, this resulted in a rapid Case–Control Study
but transient inflammatory cell infiltration accom-
panied by induction of type I IFN production by Langan SM, Groves RW, West J
plasmacytoid dendritic cells (PDCs) and release of King’s College, London, UK
extracellular traps and proinflammatory cytokines
by neutrophils. These responses were strongly Journal of Investigative Dermatology 2011, 131:
reduced in MyD88-deficient mice and in mice 631-36
treated with a bifunctional inhibitor of TLR7 and
TLR9. In contrast, in lupus-prone (NZBxNZW)F1 Previous small studies and case reports have sug-
mice, tape stripping induced the development of gested that neurological disorders may be associ-
chronic lesions characterized by a persistent type ated with bullous pemphigoid (BP). The objective
I IFN gene signature and many clinical and histo- of this study was to assess BP risk in patients with
logical features of cutaneous lupus. Depletion of neurological diseases. Computerized medical re-
PDCs before injury prevented the development of cords from the Health Improvement Network, a
skin lesions, whereas treatment with a bifunctional large population-based UK general practice data-
TLR7/9 inhibitor before tape stripping or after the base, were used to conduct a matched case–con-
initial lesion was established led to a significant trol analysis. Conditional logistic regression was
reduction of the disease. These data suggest that used to calculate odds ratios for specified neuro-
inhibitors of TLR7 and TLR9 signaling have poten- logical disorders. Comparing cases (n=868) to con-
tial therapeutic application for the treatment of trols (n=3,453), stroke was seen in 8 vs. 5%, odds
interface dermatitis. ratio (OR) 1.8 (1.3–2.5); dementia in 7 vs. 2%, OR
3.4 (2.4–4.8); Parkinson’s disease in 3 vs. 1%, OR 3.0
(1.8–5.0); epilepsy in 2 vs. 1%, OR 1.7 (1.0–3.0); and
multiple sclerosis in 1 vs 0.1% (OR 10.7 (2.8–40.2).
Estimates were not altered greatly when diagno-
Detection of Merkel Cell Polyomavirus in Epi- ses up to 3 years before BP were excluded, except
dermodysplasia-Verruciformis-Associated Skin the association with epilepsy was no longer sig-
Neoplasms nificant. Significant associations were only ob-
served where neurological disease was diagnosed
Mertza KD, Schmida M, Burgerd B, Itind P, Palmedoe before the onset of pemphigoid. Study findings,
G, Schärere L, Kutznere H, Fernández Figueras MT,
except the association with epilepsy, were robust
Cribierg B, Pfaltza M, Kempfa W
to sensitivity analysis. Strong associations were
University Hospital Zurich, Zurich, Switzerland
observed between specific neurological diseases
and the later development of BP, supporting pos-
Dermatology 2011, 222(1): 87-92
sible causal associations. Mechanisms for disease
occurrence based on these findings include im-
Background: Epidermodysplasia verruciformis
mobility or age-related autoimmunity.
(EV) is a rare genodermatosis that is character-
ized by susceptibility to infection with specific
J O U R N A L C LU B
human papillomavirus (HPV) genotypes. Among
polyomaviruses, the novel Merkel cell polyomavi-
rus (MCPyV) has been found in different epithelial "Management by committee is never suc-
skin neoplasias. Objective: To examine whether
EV is associated with cutaneous MCPyV infection.
cessful and usually adds up to no manage-
Methods: We used MCPyV-specific PCR to study ment at all."
skin neoplasms of 6 congenital EV patients and
of 1 patient with acquired EV. Results: In all con- Shelley, Walter B.
genital EV patients, MCPyV DNA was found in "Advanced Dermatologic Diagnosis"
carcinomas in situ, in invasive squamous cell car- W.B. Saunders 1992
cinomas and in common warts. In 4 of these pa-
tients, the MCPyV-positive skin lesions were from
6
Pump-Probe Imaging Differentiates Melanoma chitectural differences. We examined slices from
from Melanocytic Nevi 42 pigmented lesions and found that melanomas
had an increased eumelanin content compared
Matthews TE, Piletic IR, Selim MA, Simpson MJ, War- to nonmalignant nevi. When used as a diagnostic
ren WS criterion, the ratio of eumelanin to pheomelanin
Duke University Medical Center, Durham, USA captured all investigated melanomas but ex-
cluded three-quarters of dysplastic nevi and all
Science Translational Medicine 2011, 3(71) benign dermal nevi. Additional evaluation of ar-
71ra15 chitectural and cytological features revealed by
multiphoton imaging, including the maturation
Melanoma diagnosis is clinically challenging: the of melanocytes, presence of pigmented mel-
accuracy of visual inspection by dermatologists anocytes in the dermis, number and location of
is highly variable and heavily weighted toward melanocytic nests, and confluency of pigmented
false positives. Even the current gold standard cells in the epidermis, further increased specific-
of biopsy results in varying diagnoses among ity, allowing rejection of more than half of the re-
pathologists. We have developed a multiphoton maining false-positive results. We then adapted
technique (based on pump-probe spectroscopy) this multiphoton imaging technique to hema-
that directly determines the microscopic distri- toxylin and eosin (H&E)–stained slides. By adding
bution of eumelanin and pheomelanin in pig- melanin chemical contrast to H&E-stained slides,
mented lesions of human skin. Our initial results pathologists will gain complementary informa-
showed a marked difference in the chemical vari- tion to increase the ease and accuracy of mela-
ety of melanin between nonmalignant nevi and noma diagnosis.
melanoma, as well as a number of substantial ar-
J O U R N A L C LU B
Figure 1: Malignant melanoma compared with a benign nevus. (A) Malignant melanoma imaged at 0-fs interpulse delay,
showing melanin localized mainly to the basal layer at the edge of the lesion (arrow) and deep in the papillary dermis at
the center. (B) Increasing the interpulse distance to 300 fs showed that the center of the melanoma contained far more
eumelanin than the regions of normal tissue. (C) Fractional eumelanin content of the same melanoma. The arrow labels
the basal layer. (D) H&E-stained slice of the same melanoma, melanocytes in the dermis labeled with an arrow. (E) Mosaic
image of a benign nevus at 0-fs interpulse delay. Melanin was localized only to the basal layer of the epidermis (arrow).
(F) Increasing the interpulse delay to 300 fs showed that the nevus had little eumelanin content. (G) Fractional eumelanin
content image; this nevus was pheomelanic and uniformly pigmented. Arrows in (E) to (G) mark the base of the epider-
mis. (H) H&E-stained slice of the same nevus. Melanocytes were found in the dermis, which had no melanin pump-probe
signal (arrow), indicating that they have matured and are of little clinical concern. Scale bars, 100 μm. Arrowheads denote
the surface of the skin..
7
A Randomized Comparison of Methods of Selecting Objective: We sought to examine the preliminary ef-
Narrowband UV-B Starting Dose to Treat Chronic ficacy and safety of ABT-874 for moderate to severe
Psoriasis psoriasis beyond 12 weeks.
Methods: Patients with chronic plaque psoriasis who
Objectives: To compare narrowband UV-B (TL-01 responded to ABT-874 during the initial randomized,
lamp) phototherapy for psoriasis with individual placebo-controlled, 12-week study phase were eli-
patient starting doses based on minimal erythemal gible for a 36-week observation/retreatment phase.
dose (MED) determination vs a standard fixed start- During the subsequent 60-week, open-label exten-
ing dose and to compare the efficacy of 70% of MED sion phase, eligible patients were retreated with one
vs 50% of MED starting dose regimens. of two ABT-874 dosages. Efficacy was measured us-
Design: Single-center, randomized, double-blind, ing Psoriasis Area and Severity Index and physician
clinical trial. global assessment scores; safety was monitored by
Setting: Department of Dermatology, Ninewells Hos- adverse events (AEs), laboratory parameters, and vi-
pital and Medical School, Dundee, Scotland. tal signs.
Patients : A total of 210 adult patients (207 of skin Results: During the observation/retreatment phase,
phototypes I to III) referred for narrowband UV-B to 130 of 180 patients were eligible for retreatment. Af-
treat chronic psoriasis. The study was designed to ter 12-week retreatment with ABT-874, 55% to 94% of
have 90% power to detect a difference of 3 or more retreated patients (n = 58) achieved a 75% or greater
treatments to clearance and/or minimal residual ac- reduction in Psoriasis Area and Severity Index score.
tivity (MRA) between groups. Among patients receiving ABT-874 through the first
Interventions: Narrowband UV-B phototherapy was 48 weeks, there were no deaths and 4 patients with
given according to 3 standard regimens, differing serious AEs; one patient discontinued because of an
only by starting dose selection method. The random- AE. During the open-label extension (N = 105), there
ly allocated starting doses were (1) a fixed starting were no deaths or serious infections, and 3 serious
dose, (2) 70% of individual MED, and (3) 50% of indi- AEs.
vidual MED. All patients were MED tested to ensure Limitations: Lack of placebo or active comparator
blinding and for safety reasons. groups limited statistical analysis in later study phas-
Main Outcome Measures : The number of treatments es. Dosing differences existed between groups, and
to clearance and/or MRA of psoriasis was the primary only week-12 responders were eligible for retreat-
efficacy outcome measure, with changes in Psoriasis ment.
Area and Severity Index and Psoriasis Disability Index
scores as secondary measures. Adverse effects were Journal of the American Academy of Dermatology
FOCUS - Psoriasis
recorded. 2011, 64(2): 263-74
Results: There were no significant differences in the
number of treatments to clearance and/or MRA How stress gets under the skin: cortisol and stress
across all 3 groups or in the percentages achieving reactivity in psoriasis
clearance in each group. More uncomfortable ery-
themas occurred in the 50% of MED starting dose Background: Psychological stressors might contrib-
group (39%) than in the 70% of MED starting dose ute to the severity of chronic inflammatory diseases
group (24%) or the fixed starting dose group (24%) such as psoriasis by dysregulating hypothalamic–
(P = .07). pituitary–adrenal (HPA) axis activity.
Conclusions: The methods of determining the start- Objectives: To evaluate the role of cortisol, a key com-
ing dose in this predominantly skin phototype I and ponent of the HPA axis, in reaction to psychological
II population, treated 3 times weekly, with a 20% fol- stress in patients with psoriasis.
lowed by 10% incremental reduction in dose, did not Methods: Serum cortisol, clinical indicators of disease
significantly influence the effectiveness of treatment. severity (Psoriasis Area and Severity Index) and self-
Had there been a clinically important difference in ef- report measures of daily stressors were measured
ficacy, we would have expected to identify this. Thus, monthly for 6 months in 62 patients with psoriasis.
basing starting dose on individual MED assessments Results: In addition to the previous findings in this
may not influence the treatment’s efficacy in a skin sample showing that peak levels of daily stressors
phototype I to III population, although it remains predicted an increase in disease severity a month
important for patient safety. It remains possible that later, the peak levels of daily stressors were also
in populations containing individuals with a broader significantly associated with a lower cortisol level.
range of erythemal sensitivity, basing the starting Moreover, patients who persistently experienced
dose on MED testing could have an important im- higher levels of daily stressors had lower mean corti-
pact on treatment effectiveness. sol levels than patients who experienced lower levels
of daily stressors.
Archives of Dermatology 2011, 147(2): 168-74 Conclusions: Results suggest that daily stressors in-
fluence disease outcome in patients with psoriasis
by affecting cortisol levels at moments of high stress.
Furthermore, patients with persistently high levels of
Efficacy and Safety of ABT-874, a Monoclonal Anti- stressors seem to have a specific psychophysiologi-
interleukin 12/23 Antibody, for the Treatment of cal profile of lowered cortisol levels and may be par-
Chronic Plaque Psoriasis: 36-Week Observation/ ticularly vulnerable to the influence of stressors on
Retreatment and 60-Week Open-label Extension their psoriasis.
Phases of a Randomized Phase II Trial
British Journal of Dermatology 23011, 163(5): 986–
Background: ABT-874, an antieinterleukin-12 and -23 991
antibody, was previously shown to be significantly
more effective compared with placebo during a 12-
week phase II study of psoriasis. We report here safe-
ty and efficacy data of ABT-874 during subsequent
phases of this study.
8
…DENN IN DER TIEFE LAUERT DIE GEFAHR!
• BEWÄHRT BEI
ATOPISCHER DERMATITIS 1, 2, *
• WIRKSAMER ALS
PIMECROLIMUS CREME 3
• KEINE HAUTATROPHIE 4, 5
* Protopic® ist indiziert zur Behandlung akuter Exazerbationen von mittelschwerer bis schwerer atopischer Kinder ab 2 Jahren und Jugendliche: 2x täglich eine dünne Schicht Salbe 0.03% auf die Hautläsionen
Dermatitis als „Second-Line“-Therapie, falls die herkömmliche Behandlung nicht genügend wirksam ist auftragen. Die Behandlung ist auf die Hautläsionen zu beschränken. Eine kontinuierliche
oder Nebenwirkungen auftreten. Langzeitanwendung sollte vermieden werden. KI: Patienten mit bekannter Überempfindlichkeit
auf Tacrolimus oder auf einen der Hilfsstoffe der Salbe. VM: Protopic®-Salbe ist an Kindern unter
Referenzen: 1. Rustin, M. H.: The safety of tacrolimus ointment for the treatment of atopic dermatitis: 2 Jahren nicht geprüft worden. Übermässige UV-Exposition (UVA- oder UVB-Strahlen) der
a review. Br J Dermatol, 2007; 157(5): 861-873. 2. Reitamo, S. et al.: A 4-year follow-up study of atopic behandelten Hautpartien, z.B. Sonne oder Solarium, ist während der ganzen Behandlungsdauer
dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol, zu vermeiden. Geeignete Sonnenschutzmassnahmen sind vom Arzt zu empfehlen. Gleichzeitig
2008; 159(4): 942-951. 3. Paller, A.S. et al.: Tacrolimus ointment is more effective than pimecrolimus mit Protopic® können Emollienzien angewendet werden, wobei zwischen den Applikationen der
cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, beiden Präparate auf derselben Hautpartie mindestens 2 Stunden liegen sollten. Schwangerschaft,
comparative studies. J Am Acad Dermatol 2005; 52(5): 810-822. 4. Kyllönen, H. et al.: Effects of 1-year Stillzeit: Während der Schwangerschaft darf Protopic® nicht verwendet werden, es sei denn, dies
intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients ist unbedingt erforderlich. Obschon die systemische Resorption von Tacrolimus bei Applikation
with atopic dermatitis. Br J Dermatol, 2004; 150(6): 1174-1181. 5. Reitamo, S. et al.: Tacrolimus der Salbe beschränkt ist, empfiehlt es sich, während der Behandlung mit Protopic® nicht zu stillen.
ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest UW: Hautreizungen an der Applikationsstelle: Hautbrennen, Pruritus, Wärmegefühl, Hautrötung,
Dermatol, 1998; 111(3): 396-398. Schmerz, Reizung, Ausschlag, Follikulitis, Parästhesien und Dysästhesien. Andere: Herpesvirus-
APCHPRTIN0411d
Infektionen, Herpes simplex, Akne, Alkoholunverträglichkeit. IA: Da Tacrolimus nicht durch die
Gekürzte Fachinformation von Protopic®: Z: Protopic®-Salbe 0.03% und 0.1% enthalten: Haut metabolisiert wird, besteht kein Risiko einer perkutanen Interaktion, die den Metabolismus
0.3 mg/g bzw. 1 mg/g Tacrolimus, Excip. ad unguentum. I: Behandlung akuter Exazerbationen von Tacrolimus beeinträchtigen könnte. P: Salbe 0.1% 10 g, 30 g und 60 g, Salbe 0.03% 10 g, 30 g
von mittelschwerer bis schwerer atopischer Dermatitis als „Second-Line“-Therapie, falls die und 60 g. Liste B, kassenpflichtig. Vor der Verschreibung konsultieren Sie bitte das Arzneimittel-
herkömmliche Behandlung nicht genügend wirksam ist oder Nebenwirkungen auftreten. D: Kompendium der Schweiz®. Zulassungsinhaberin Astellas Pharma AG, Grindelstrasse 6, 8304
Erwachsene: 2x täglich eine dünne Schicht Salbe 0.03% oder 0.1% auf die Hautläsionen auftragen. Wallisellen. Stand der Information: März 2006
Critical Appraisal of Quality of Clinical Practice Nail Psoriasis Successfully Treated with Intralesion-
Guidelines for Treatment of Psoriasis Vulgaris, al Methotrexate: Case Report
2006–2009
Psoriasis is a common, chronic disease which affects
Numerous international clinical guidelines for man- nearly 3% of the population. The lifetime incidence
agement of psoriasis have recently been published. of nail involvement increases up to 80–90% for psori-
We evaluated the quality of guidelines published be- atic patients. Nail psoriasis is considered a significant
tween 2006 and December 2009 using the Appraisal social problem. Many topical agents have been used
of Guidelines Research and Evaluation (AGREE) in- for psoriatic nails with various side effects and some
strument. Eight guidelines from five separate work- benefits; management is currently inconclusive.
ing groups fulfilled inclusion criteria and were evalu- Methotrexate (MTX) is a folic acid analog, which irre-
ated. Four used the standards established by the versibly binds to dehydrofolate reductase and blocks
AGREE instrument in the process of development deoxyribonucleic acid synthesis. It is considered a
of their guidelines. Each of the guidelines uniformly potential treatment option for rapidly growing cells
received high domain scores (i.e., >90%) for scope and has an anti-inflammatory effect through inhibi-
and purpose (range of 94–100%), and clarity and tion of the polyamine pathway in autoimmune dis-
presentation (range of 92–100%). Nevertheless, each eases. Intralesional MTX has been used successfully
of the eight guidelines had important shortcomings for various indications. We present a case success-
(item scores 2/4, in which 4 indicates strongly agree fully treated with low-dose intralesional MTX with no
and 1 indicates strongly disagree that specific items observed side effects in a 26-year-old female psori-
have been adequately addressed) in at least one item atic patient suffering from nail dystrophy. In contrast,
including: stakeholder involvement (by lack of pilot- conventional topical and systemic therapies have
ing and inadequate determination of patient views), various side effects, which limit their use. We con-
development rigor (inadequate procedure for updat- clude that intralesional MTX injection seems to be a
ing), applicability (by lack of discussion on organiza- safe and effective treatment option for nail psoriasis;
tional barriers), and editorial independence (from however, large controlled studies are needed.
funding body). Despite the use of predefined stan-
dards in their development, important deficiencies Dermatology 2011, 222(1): 5-7
exist in the most recent clinical treatment guidelines
for psoriasis.
Journal of Investigative Dermatology 2010, 130: Gene from a Psoriasis Susceptibility Locus Primes
2389–2395 the Skin for Inflammation
Psoriasis is a common complex genetic disease
characterized by hyperplasia and inflammation
Resolved Psoriasis Lesions Retain Expression of a in the skin; however, the relative contributions of
Subset of Disease-Related Genes epidermal cells and the immune system to disease
pathogenesis remain unclear. Linkage studies have
Psoriasis is a complex inflammatory disease that usu- defined a psoriasis susceptibility locus (PSORS4) on
ally heals without visible scarring. Histological evalu- 1q21, the epidermal differentiation complex, which
ation often suggests complete resolution, but rever- includes genes for small S100 calcium-binding pro-
sal of genomic disease-associated alterations has teins. These proteins are involved in extracellular and
not yet been defined. Gene expression profiling was intracellular signaling during epithelial host defense,
used to determine the extent to which the psoriasis linking innate and adaptive immunity. Inflammation-
genes were reversed after 3 months of etanercept prone psoriatic skin constitutively expresses elevated
treatment in patients who responded to treatment. concentrations of S100A7 (psoriasin) and S100A15
We reviewed the histology, leukocyte counts, and (koebnerisin) in the epidermis. Here, we report
PCR data for inflammatory genes, to compare recov- that genetically modified mice expressing elevated
ery of these parameters and the genomic studies. amounts of doxycycline-regulated mS100a7a15 in
Many cellular markers do return close to nonlesional skin keratinocytes demonstrated an exaggerated
levels, although five inflammatory genes did not inflammatory response when challenged by exog-
improve by >75% (IL-12p35, MX1, IL-22, IL-17, and enous stimuli such as abrasion (Koebner phenom-
IFNγ). Psoriasis-related genes with7UDLWHPHQWGHODNÒUDWRVHDFWLQLTXH
8QHHIðFDFLWÒGXUDEOHSDUIDLWHPHQWFLEOÒH
6WLPXOHO¿RśFâHVWQÒFHVVDLUHOHV\VWÑPHLPPXQLWDLUHHQGRJÑQHGHODSHDX
$OGDUDė&UÑPH (LHPTHLNCHLLTMNLNCTK@SDTQ ,QGLFDWLRQV SQ@HSDLDMSSNOHPTDCDK@CTKSD "NMCXKNLDR@BTLHMġRDWSDQMDRC@MRK@YNMDFġMHS@KDDSOġQH@M@KD "@QBHMNLDRA@RNBDKKTK@HQDRRTODQjBHDKRLTKSHOKDRBNMjQLġRO@QAHNORHDCH@LĠSQDSTLNQ@K
L@WHL@KBL@TMHUD@TCTSQNMBĐKDWBKTRHNMCDK@QġFHNM@M@KDDSFġMHS@KD @TMHUD@TCTBNTNT@TWDWSQġLHSġRĐKDWBKTRHNMCDRL@HMRDSCDROHDCR KNQRPTTMDDWBHRHNMBGHQTQFHB@KDMDRSO@RHMCHPTġDDSPTDKDRTHUHDRSF@Q@MSH *ġQ@SNRDR@BSHMHPTDR MNM
GXODQJġQ@SNRHPTDR MNMGXODQSQNOGHPTDR BKHMHPTDLDMSSXOHPTDR KNB@KHRġDRRTQKDUHR@FDDSK@SĢSD 3RVRORJLH @OOKHPTDQQDRODBSHUDLDMS@U@MSKDBNTBGDQ "NMCXKNLDR@BTLHMĠRDWSDQMDR@OOKHPTDQTMDBNTBGDLHMBDWRDL@HMD@TL@WHLTLRDL@HMDR
K@BQĠLDCNHSQDRSDQlG@TBNMS@BSCDK@OD@T "@QBHMNLDA@RNBDKKTK@HQDRTODQkBHDKODMC@MSRDL@HMDR WRDL@HMDK@BQĠLDCNHSQDRSDQG@TBNMS@BSCDK@OD@T *ĠQ@SNRD@BSHMHPTDODMC@MSRDL@HMDRWRDL@HMDK@BQĠLDCNHSQDRSDQG@TBNMS@BS
CDK@OD@T &RQWUHLQGLFDWLRQV GXODQRDMRHAHKHSġ@TOQHMBHOD@BSHENTĐTMDWBHOHDMS 3Q@HSDLDMSCDRDME@MSRDS@CNKDRBDMSR 3UÒFDXWLRQV TKBĠQDRNTUDQSR OK@HDRNTUDQSDR HMSDQUDMSHNMRBGHQTQFHB@KDRTMHPTDLDMS@OQĠRBHB@SQHR@SHNMBNLOKĠSD /@RCDO@MRDLDMS
NBBKTRHE ġUHSDQKDBNMS@BS@UDBKDRXDTW KDRKĠUQDRDSK@LTPTDTRDM@R@KD ġUHSDQKDWONRHSHNMCDK@OD@TSQ@HSġD@TRNKDHK /NRRHAKD@FFQ@U@SHNMCDRL@MHEDRS@SHNMRBTS@MġDRHMk@LL@SNHQDR /QTCDMBDBGDYKDRO@SHDMSRSQ@MROK@MSġRNTONQSDTQRCTMDL@K@CHD
@TSNHLLTMD #DUHNKDMSDRQġ@BSHNMRBTS@MġDRHMk@LL@SNHQDRKNB@KDRRNMSONRRHAKDR /QTCDMBDDMB@RCDSQ@HSDLDMSCTOQġOTBDBGDYKGNLLDMNMBHQBNMBHR #ġBNMRDHKKġDMB@RCDBNMCXKNLDR@BTLHMġRHMSDQMDRCDK@QġFHNMFġMHS@KD /DMC@MSFQNRRDRRD
DS@KK@HSDLDMSTMHPTDLDMSDMB@RCDMġBDRRHSġ@ARNKTD 1DBNLL@MC@SHNMRBNMBDQM@MSKDRQ@OONQSRRDWTDKRDSK@BNMSQ@BDOSHNMDMB@RCDBNMCXKNLDR@BTLHMġR DS@TSQDRLHRDRDMF@QCDDSOQġB@TSHNMRCDLOKNHRDKNMKDRHMCHB@SHNMRUNHQKD"NLODMCHTL
,QWHUDFWLRQV MNMġSTCHġDR .MMDCNHSR@SSDMCQDPTDC@MRTMDSQĠRE@HAKDLDRTQDĐCDRHMSDQ@BSHNMR@UDBCDROQHMBHODR@BSHERC@OOKHB@SHNMSNOHPTD /QTCDMBDBGDYKDRO@SHDMSRRTHU@MSTMSQ@HSDLDMSHLLTMNRTOOQDRRDTQ (IIHWVLQGÒVLUDEOHV 3QĠREQġPTDMSR
Qġ@BSHNMR@TRHSDC@OOKHB@SHNMITRPTĐ %QġPTDMSRHMEDBSHNMRBġOG@KġDRLX@KFHDOQTQHS CNTKDTQR AQŖKTQDR@TRHSDC@OOKHB@SHNME@SHFTD $(ŰŰUNHQKD"NLODMCHTL 3UÒVHQWDWLRQ $.CDR@BGDSRĐTR@FDTMHPTD $ $GPLVSDUOHVFDLVVHVPDODGLH
(MENQL@SHNMRCġS@HKKġDRMNSHBDCDLA@KK@FD "NLODMCHTL2THRRDCDR,ġCHB@LDMSRNT,$# /G@QL@&LA' 6@MFDM !QŘSSHRDKKDM ,HRDĐINTQCDKHMENQL@SHNML@H
*Q@VSBGDMJN-DS@K Q@MCNLHRDCRSTCXNESNOHB@KHLHPTHLNCUR SNOHB@K kTNQNTQ@BHKUR BQXNRTQFDQXHMHLLTMNBNLODSDMSO@SHDMSRVHSG@BSHMHBJDQ@SNRDR@BNLO@QHRNMNEBKHMHB@K@MCGHRSNKNFHB@KNTSBNLDRHMBKTCHMF XD@Q
ENKKNV TO !)#2TOOK lPRé-PROGRAMME
93 Réunion Annuelle de la Société Suisse
ème
de Dermatologie et Vénéréologie
31 Août - 3 Septembre 2011, Genève, Starling Geneva Hotel & Conference Center
VORPROGRAMM
93. Jahresversammlung der Schweizerischen
Gesellschaft für Dermatologie und Venerologie
31. August - 3. September 2011, Genf, Starling Geneva Hotel & Conference Center
La réunion annuelle 2011 aura un niveau international et se présentera sous forme d’un joint-venture
avec l’ International Society of Dermatopathology (ISDP) – deux congrès – un sujet et comme vous
allez le découvrir dans le programme scientifique, des conférences plenières d’une renommée mon-
diale pour tous les participants du congrès.
L’ organisation d’un tel congrès demande quelques compromis et c’est pourquoi le site du congrès
est présenté seulement en anglais. Il va de soi que le congrès lui-même sera mené dans les langues
nationales comme d’habitude.
Mais il y a aussi du nouveau:
* Jeudi, 1er septembre 2011, des Lunch Sessions – (une nouveauté en Suisse) auront lieu avant les
workshops de la SSDV
* l’inscription se fera en ligne sur http://www.isdpssdv2011.com. En plus vous y trouverez tous
les renseignements nécessaires.
Merci de votre inscription!
Die Jahresversammlung wird auf internationalem Niveau in Form eines Jointventures mit der International
Society of Dermatopathology (ISDP) stattfinden, zwei Kongresse – ein Thema und wie Sie dem Programm
entnehmen können, einige gemeinsame Plenum von internationaler Grösse für alle Teilnehmer.
Die Organisation eines Kongresses von solcher Grösse fordert einige wenige Kompromisse und so ist zum
Beispiel die Webseite nur auf Englisch gehalten, der Anlass wird jedoch wie üblich in den Landessprachen
durchgeführt.
Weiter bietet ein solcher Anlass aber auch Raum für Neues:
* am Donnerstag, 1. September 2011, finden im Vorfeld zu den SGDV-Workshops von 12h30 –14h00 zum
ersten Mal in der Schweiz Lunch Sessions statt (mehr dazu im Programm)
SGDV - SSDV
* Einfache und praktische Online-Registrierung auf http://www.isdpssdv2011.com. Auf dieser Kongress-
homepage finden Sie auch alle weiteren nötigen Informationen zur Jahresversammlung.
Besten Dank für Ihre Anmeldung!
New Frontiers in Dermatology
Mercredi 31 août - Mittwoch 31. August 2011
12.00 - 19.00 Enregistrement - Anmeldung
15.00 - 17.00 Séances de la commission des directeurs de cliniques SSDV
Klinikdirektorenkommissionssitzung SGDV
17.00 - 22.00 Séance du Comité SSDV
Vorstandssitzung SGDV
Jeudi 1 septembre - Donnerstag 1. September 2011
07.30 - 19.30 Enregistrement - Anmeldung - Poster mounting
08.30 - 10.00 Comité élargi de la SSDV
erw. Vorstandssitzung SGDV
10.00 - 10.30 Pause Café - Poster - Kaffeepause
10.30 - 12.30 Swiss Dermatology Network for Targeted Therapies (SDNTT) Meeting
12.30 - 13.30 Swiss Group of Dermatopathology (SGDP) Meeting
12.30 - 13.30 Comité - Vorstand Dermarena
12.30 - 14.00 Déjeuner/Poster - Mittagessen/Poster
12Z: 1 g Pruri-med Lipolotion enthält: Ureum 50 mg, polidocanolum 600 30 mg. I: Hauterkrankungen mit trockener und/oder juckender Haut wie z.B. atopische Dermatitis und
Pruritus senilis. D: 2-3 mal täglich auftragen. UW: auf entzündeter Haut gelegentlich Brennen, Rötung. P: 200 ml* + 500 ml*. Liste D. Z: 1 g Pruri-med enthält: Polidocanolum 600
50 mg, disodium undecylenamido MEA-sulfosuccinate 30 mg. I: Therapieunterstützende, antipruriginöse Hautreinigung bei atopischer Dermatitis, Urtikaria, Pruritus senilis oder
sine materia. D: wie flüssige Seife anwenden. P: 150 ml* + 500 ml*. Liste D. Ausführliche Informationen siehe Arzneimittel-Kompendium der Schweiz. Permamed AG, CH-4106
Therwil, Tel. 061 725 20 20, Fax 061 725 20 40, e-mail: permamed@permamed.ch, www.permamed.ch, Pru/ins/D/12-10
200 ml (SL)
s Pruritus senilis
s Atopische Dermatitis
s 200 ml + 500 ml kassenpflichtig
und juckende Haut
Pruri-med Lipolotion
®
auch 500 ml
Die Oase für sehr trockene
s 5% Ureum
s 40% Lipide
kassenpflichtig (SL)
s 3% Polidocanol 60012.30 - 14.00 Lunch sessions: "All You Want to Know About"
Discussion de thèmes au déjeuner avec des experts /
Themendiskussionen bei Lunch mit Experten
S. Fraitag (France) - Pediatric Dermatology
J. André (Belgium) - Nail Diseases
R. Cerio (UK) - Aggressive Skin Cancer
D. Metze (Germany) - Disorders of Cornification
L. Requena (Spain) - Adverse Reactions to Injectable Fillers
14.00 - 15.30 Workshops Partie - TeiI I
Skincare (SGEDS)
Trichologie
Transplantation
Andrologie
15.30 - 16.00 Pause Café - Poster - Kaffeepause
16.00 - 17.30 Workshops Partie - TeiI II
Dermatochirurgie
Dermatoallergologie
Dermatopädiatrie
Clinical Skills
17.30 - 18.00 Pléniaire - Plenum III (SSDV / ISDP)
ISDP/SSDV COMMON SESSION Bruce Smoller (USA) - The Impact of Clinical Photos on Diagnosis
in Inflammatory Skin Diseases and Melanocytic Lesions
18.00 - 18.30 Pléniaire - Plenum IV (SSDV / ISDP)
ISDP/SSDV COMMON SESSION Phillip McKee (USA) - The Role of Clinicopathological Correlation
in Dermatopathology
18.30 - 19.00 Cérémonie d’ouverture - Eröffnungszeremonie
Exposition - Ausstellung
19.00 - 20.00 Apéro - Apéro
Exposition - Ausstellung
20.00 - 23.00 Comité - Vorstands - Presidents - Speakers Dinner
Vendredi 2 septembre - Freitag 2. September 2011
07.30 - 19.30 Enregistrement - Anmeldung
08.15 - 08.30 Bienvenue - Willkommen: G. Kaya
08.30 - 09.00 Plenary Lecture I
Bernard Cribier (France): Multiple Facial Papules: From Pimples to
Cancer Prone Diseases
09.00 - 09.30 Communications libres - Freie Mittelungen I (ZH/BE/BS)
09.00 - 17.00 Nurse meeting
09.30 - 10.00 Plenary Lecture II
Jean-Hilaire Saurat (Switzerland): Drug-Induced Acne
10.00 - 10.30 Présentation des cas - Fall Vorstellungen I (LU/BE/SG)
10.30 - 11.00 Pause Café - Poster - Kaffeepause
11.00 - 11.30 Plenary Lecture III
Martin C. Mihm (USA): Hemangiomas and Vascular Malformations:
An Overview, Diagnosis and Treatment
11.30 - 12.00 Communications libres - Freie Mittelungen II (ZHT/AG/SG)
12.00 - 12.30 Présentation des cas - Fall Vorstellungen II (AG/BS/BEL)
12.30 - 14.00 Déjeuner/Poster - Mittagessen/Poster
Satellites symposiums - Sateliten Symposien
14.00 - 15.00 Ackerman lecture (SSDV / ISDP)
ISDP/SSDV COMMON SESSION Rolf Heuer (CERN - Switzerland) - The Large Hadron Collider:
Shedding Light on the Dark Universe
15.00 - 16.00 Test Yourself - Dermatopathology Quiz (SSDV / ISDP)
ISDP/SSDV COMMON SESSION Rino Cerio (UK) - Omar Sangüeza (USA)
16.00 - 16.30 Pause Café - Poster - Kaffeepause
16.30 - 17.30 Séminaire politique - Berufspolitisches Seminar
SGDV - SSDV
17.30 - 19.00 SSDV Assemblée Générale - SGDV Generalversammlung
20.00 - 23.00 Congress Dinner
Samedi 3 septembre - Samstag 3. September 2011
07.30 - 14.30 Enregistrement - Anmeldung
08.00 - 08.30 Plenary Lecture IV
Rachael Clark (USA): Skin Resident T Cells in Health and Disease
08.30 - 09.00 Présentation des cas - Fall Vorstellungen III (ZHT)
14Z: 1 g Squa-med enthält: Pyrithionum zincicum 15 mg, disodium undecylenamido MEA-sulfosuccinate 20 mg. I: Seborrhoische Dermatitis, Pityriasis simplex capitis, Psoriasis
des behaarten Kopfes. D: 1–2 mal wöchentlich Squa-med auf gut angefeuchtete Haare einreiben, spülen, Squa-med nochmals einmassieren, 3–5 Minuten einwirken lassen
und gründlich spülen. VM: nicht in die Augen bringen. P: 150 ml*. Liste D. Ausführliche Informationen siehe Arzneimittel-Kompendium der Schweiz.
Permamed AG, CH-4106 Therwil, Tel. 061 725 20 20, Fax 061 725 20 40, E-Mail: permamed@permamed.ch, www.permamed.ch SM/Ins/D/01-10
Seborrhoische Dermatitis09.00 - 09.30 Plenary Lecture V
Thomas Kupper (USA): Cutaneous T Cell Lymphoma and T Cell
Trafficking
09.30 - 10.10 Communications libres - Freie Mittelungen III (GE/LS/LU/BEL)
10.10 - 10.40 Présentation des cas - Fall Vorstellungen IV (LS)
10.40 - 11.00 Pause Café - Poster - Kaffeepause
11.00 - 11.30 Présentation des cas - Fall Vorstellungen V (ZH)
11.30 - 12.00 Plenary Lecture VI
Andrew Carlson (USA): Cutaneous Vasculitis Update: New Entities,
Changing Paradigms
12:00 - 12:30 Présentation des cas - Fall Vorstellungen VI (GE)
12:30 - 13:00 Plenary Lecture VII
Raymond Barnhill (France): Mechanisms of melanoma metastasis:
A Historical Critique and New Observations
13.00 Conclusions - Schlussfolgerung
New Frontiers in Dermatology
Version anglaise - Englische Version
Wednesday 31st August 2011
12.00 - 19.00 Registration
15.00 - 17.00 Department Directors’ Meeting
17.00 - 22.00 SSDV Committee Meeting
Thursday 1st September 2011
07.30 - 19.30 Registration and Poster mounting
08.30 - 10.00 SSDV Enlarged Committee Meeting
10.00 - 10.30 Coffee Break - Exhibition - Poster Session
10.30 - 12.30 Swiss Dermatology Network for Targeting Therapies (SDNTT) Meeting
12.30 - 13.30 Swiss Group of Dermatopathology (SGDP) Meeting
12.30 - 13.30 Dermarena Meeting
12.30 - 14.00 Lunch - Poster Session
Lunch Sessions: "All You Want to Know About"
S. Fraitag (France) - Pediatric Dermatology
J. André (Belgium) - Nail Diseases
R. Cerio (UK) - Aggressive Skin Cancer
D. Metze (Germany) - Disorders of Cornification
L. Requena (Spain) - Adverse Reactions to Injectable Fillers
14.00 - 15.30 Workshops I
Skin Care
Trichology
Transplantation
Andrology
15.30 - 16.00 Coffee Break - Exhibition - Poster Session
16.00 - 17.30 Workshops II
Surgical Dermatology
Dermatoallergology
Pediatric Dermatology
Clinical Skills
17.30 - 18.00
SGDV - SSDV
Plenary Lecture III (SSDV / ISDP)
ISDP/SSDV COMMON SESSION Bruce Smoller (USA) - The Impact of Clinical Photos on Diagnosis
in Inflammatory Skin Diseases and Melanocytic Lesions
18.00 - 18.30 Plenary Lecture IV (SSDV / ISDP)
ISDP/SSDV COMMON SESSION Phillip McKee (USA) - The Role of Clinicopathological Correlation
in Dermatopathology
18.30 - 19.00 Opening Ceremony
19.00 - 20.00 Welcome Reception
20.00 - 23.00 President’s Dinner
16Friday 2nd September 2011
07.30 - 19.30 Registration
08.15 - 08.30 Welcome and Introduction: G. Kaya
08.30 - 09.00 Plenary Lecture I
Bernard Cribier (France): Multiple Facial Papules: From Pimples to
Cancer Prone Diseases
09.00 - 09.30 Free Communications I (ZH/BE/BS)
09.00 - 17.00 Nurse Meeting
09.30 - 10.00 Plenary Lecture II
Jean-Hilaire Saurat (Switzerland): Drug-Induced Acne
10.00 - 10.30 Case Presentations I (LU/BE/SG)
10.30 - 11.00 Coffee Break - Exhibition - Poster Session
11.00 - 11.30 Plenary Lecture III
Martin C. Mihm (USA): Hemangiomas and Vascular Malformations:
An Overview, Diagnosis and Treatment
11.30 - 12.00 Free Communications II (ZHT/AG/SG)
12.00 - 12.30 Case Presentations II (AG/BS/BEL)
12.30 - 14.00 Lunch - Satellite Symposia - Exhibition - Poster Session
14.00 - 15.00 Ackerman Lecture (SSDV / ISDP)
ISDP/SSDV COMMON SESSION Rolf Heuer (CERN - Switzerland) - The Large Hadron Collider:
Shedding Light on the Dark Universe
15.00 - 16.00 Test Yourself - Dermatopathology Quiz (SSDV / ISDP)
ISDP/SSDV COMMON SESSION Rino Cerio (UK) - Omar Sangüeza (USA)
16.00 - 16.30 Coffee Break - Exhibition - Poster Session
16.30 - 17.30 Political Seminar
17.30 - 19.00 SSDV General Assembly
20.00 - 23.00 Congress Dinner
Saturday 3rd September 2011
07.30 - 13.00 Registration
08.00 - 08.30 Plenary Lecture IV
Rachael Clark (USA): Skin Resident T Cells in Health and Disease
08.30 - 09.00 Case Presentations III (ZHT)
09.00 - 09.30 Plenary Lecture V
Thomas Kupper (USA): Cutaneous T Cell Lymphoma and T Cell
Trafficking
09.30 - 10.10 Free Communications III (GE/LS/LU/BEL)
10.10 - 10.40 Case Presentations IV (LS)
10.40 - 11.00 Coffee Break - Exhibition - Poster Session
11.00 - 11.30 Case Presentations V (ZH)
11.30 - 12.00 Plenary Lecture VI
Andrew Carlson (USA): Cutaneous Vasculitis Update: New Entities,
Changing Paradigms
12:00 - 12:30 Case Presentations VI (GE)
12:30 - 13:00 Plenary Lecture VII
Raymond Barnhill (France): Mechanisms of Melanoma Metastasis:
A Historical Critique and New Observations
13.00 Concluding Remarks: G. Kaya
Workshops
01.09.2011 - Partie 1/Teil 1: 14.00-15.30 & Partie 2/Teil 2: 16.00-17.30
Salle St. Moritz Salle Pontresina Salle Nendaz Salle Zinal
Horaires
(100) (60) (80) (40)
SGDV - SSDV
Trichologie
14.00 Skincare (SGEDS) Transplantation Andrologie
(nicht best.)
Trichologie
15.30 Skincare (SGEDS) Transplantation Andrologie
(nicht best.)
Coffeebreak
Dermatoallergo-
16.00 Dermatochirurgie Dermatopädiatrie Clinical Skills
logie (nicht best.)
Dermatoallergo-
17.30 Dermatochirurgie Dermatopädiatrie Clinical Skills
logie (nicht best
17Wednesday, 31
Wednesday, 31 August
August 2011
2011 Thursday, 11 September
Thursday, September 2011
2011
07:00 -- 07:30
07:00 07:30
07:30 -- 08:00
07:30 08:00 Registration and
Registration and Poster
Poster Mounting
Mounting (07:30
(07:30 -- 19:30)
19:30)
08:00 -- 08:15
08:00 08:15
08:15 -- 08:30
08:15 08:30
08:30 -- 08:45
08:30 08:45 Welcome and
Welcome and Introduction
Introduction
Historical aspects
Historical aspects of
of Swiss
Swiss
08:45 -- 09:00
08:45 09:00
dermatopathology
dermatopathology
SSDV Enlarged
SSDV Enlarged Committee
Committee Meeting
Meeting //
Comité Elargi
Comité Elargi de
de la
la SSDV
SSDV // Plenary Lecture
Plenary Lecture II
09:00 -- 09:30
09:00 09:30 erw. Vorstandssitzung
erw. Vorstandssitzung SGDV
SGDV Molecular dermatopathology
Molecular dermatopathology and
and
new genes
new genes in
in melanoma
melanoma
09:30 -- 10:00
09:30 10:00 Free Communications
Free Communications II
Coffee Break
Coffee Break
10:00 -- 10:30
10:00 10:30 Exhibition
Exhibition
Poster Session
Poster Session
10:30 -- 10:45
10:30 10:45
10:45 -- 11:00
10:45 11:00 Frontiers in
Frontiers in New
New Diagnostic
Diagnostic Tools
Tools
Adnexal tumors
Adnexal tumors
Pediatric dermatopathology
Pediatric dermatopathology
11:00 -- 11:15
11:00 11:15 Innate and
Innate and adaptive
adaptive immunity
immunity in
in
dermatopathology
dermatopathology
11:15 -- 11:30
11:15 11:30
Swiss Dermatology
Swiss Dermatology Network
Network for
for Targeting
Targeting
Therapies (SDNTT)
Therapies (SDNTT) Meeting
Meeting // Séance
Séance SDNTT
SDNTT //
Sitzung SDNTT
Sitzung SDNTT
11:30 -- 12:00
11:30 12:00 Free Communications
Free Communications IIII
Plenary Lecture
Plenary Lecture IIII
12:00 -- 12:30
12:00 12:30 Registration (12:00
Registration (12:00 -- 19:00)
19:00) Melanoma stem
Melanoma stem cells:
cells: Not
Not rare
rare but
but
well-done
well-done
Swiss Group
Swiss Group of
of
12:30 -- 13:00
12:30 13:00
Dermatopathology
Dermatopathology
Dermarena Meeting
Dermarena Meeting //
(SGDP) Meeting
(SGDP) Meeting //
Séance Dermarena
Séance Dermarena //
Séance SGDP
Séance SGDP //
Sitzung Dermarena
Sitzung Dermarena
Sitzung SGDP
Sitzung SGDP
13:00 -- 13:30
13:00 13:30
Lunch
Lunch
Exhibition
Exhibition
Poster Session
Poster Session
13:30 -- 13:45
13:30 13:45
Lunch Sessions:
Lunch Sessions:
“All you
“All you want
want toto know
know about”
about”
Self-assessment Course
Self-assessment Course -- Slide
Slide Pediatric dermatology
Pediatric dermatology
Viewing Group
Viewing Group II Nail diseases
Nail diseases
Aggressive skin
Aggressive skin cancer
cancer
13:45 -- 14:00
13:45 14:00 Disorders of
Disorders of cornification
cornification
Adverse reactions
Adverse reactions to
to injectable
injectable fillers
fillers
14:00 -- 14:30
14:00 14:30 Workshops II
Workshops
Skin care
Skin care
Trichology // Trichologie
Trichology Trichologie Clinico-pathologic Conference:
Clinico-pathologic Conference:
14:30 -- 15:00
14:30 15:00 Transplantation
Transplantation Puzzling diagnoses
Puzzling diagnoses
Andrology // Andrologie
Andrology Andrologie
15:00 -- 15:30
15:00 15:30
Coffee Break
Coffee Break
15:30 -- 16:00
15:30 16:00 SSDV Department
SSDV Department Directors’
Directors’ Meeting
Meeting Exhibition
Exhibition
// Poster Session
Poster Session
Séances de
Séances de la
la Commission
Commission des des
Self-assessment Course
Self-assessment Course -- Slide
Slide
Directeurs de
Directeurs de Cliniques
Cliniques SSDV
SSDV //
Viewing Group
Viewing Group IIII
16:00 -- 16:30
16:00 16:30 Klinikdirektorenkommissionssitzung
Klinikdirektorenkommissionssitzung Frontiers in
Frontiers in Special
Special Sites
Sites
SGDV
SGDV Workshops IIII
Workshops Oral diseases
Oral diseases
Surgical dermatology
Surgical dermatology // Dermatochirurgie
Dermatochirurgie Longitudinal melanonychia
Longitudinal melanonychia
16:30 -- 16:45
16:30 16:45 Dermatoallergology // Dermatoallergologie
Dermatoallergology Dermatoallergologie Genital soft
Genital soft tissue
tissue tumors
tumors
Pediatric dermatology
Pediatric dermatology // Dermatopédiatrie
Dermatopédiatrie
16:45 -- 17:00
16:45 17:00
Clinical skills
Clinical skills
17:00 -- 17:30
17:00 17:30 Free Communications
Free Communications III
III
Welcome Aperitif
Welcome Aperitif
Plenary Lecture
Plenary Lecture III
III (ISDP)
(ISDP)
17:30 -- 18:00
17:30 18:00 The impact
The impact of
of clinical
clinical photos
photos on
on diagnosis
diagnosis inin inflammatory
inflammatory skin
skin diseases
diseases and
and
melanocytic lesions
melanocytic lesions
SSDV Committee
SSDV Committee Meeting
Meeting //
Séance du
Séance du Comité
Comité SSDV
SSDV // Get Together
Get Together Party
Party Plenary Lecture
Plenary Lecture IV
IV (ISDP)
(ISDP)
18:00 -- 18:30
18:00 18:30
Vorstandssitzung SGDV
Vorstandssitzung SGDV (ISDP Board)
(ISDP Board) The role
The role of
of clinicopathological
clinicopathological correlation
correlation in
in dermatopathology
dermatopathology
18:30 -- 19:00
18:30 19:00 Opening Ceremony
Opening Ceremony
19:00 -- 19:30
19:00 19:30
Welcome Reception
Welcome Reception
19:30 -- 20:00
19:30 20:00
20:00 -- 20:30
20:00 20:30
20:30 -- 21:00
20:30 21:00
21:00 -- 21:30
21:00 21:30 President's Dinner
President's Dinner
21:30 -- 22:00
21:30 22:00
22:00 -- 23:00
22:00 23:00
18Friday, 2 September 2011 Saturday, 3 September 2011
Registration (07:30 - 19:30) Registration (07:30 - 13:00)
Friday, 22 September
Friday, September 2011
2011 Saturday, 33 September
Saturday, September 2011
2011
Social Events and other
Plenary / Pléniaire / Plenum IV
Welcome and Introduction / (07:30
Registration
Registration (07:30 -- 19:30)
19:30) Skin resident T cells in health and
Registration (07:30
Registration (07:30 -- 13:00)
13:00)
Bienvenue et Introduction / disease SSDV Sessions
Begrüssung und Einführung Social Events
Social Events and
and other
other
Plenary // Pléniaire
Plenary PlenumSelf
Pléniaire // Plenum IV Assessment Session II (Cases
IV
Welcome and
Welcome and Introduction
Introduction // Skin resident
Skin resident TT cells
cells in
in health
health and
and 11 - 20) ISDP Sessions
Plenary / Bienvenue
Pléniaire / Plenum
Bienvenue I
et Introduction
et Introduction // disease
disease SSDV Sessions
SSDV Sessions
Case Presentations / Cas Cliniques /
Multiple facialBegrüssung
papules: From
Begrüssung undundpimples
Einführung
Einführung Fallbesprechungen III Self Assessment
Self Assessment Session
Session IIII (Cases
(Cases
to cancer prone diseases ISDP / SSDV Sessions
11 -- 20)
11 20) ISDP Sessions
ISDP Sessions
Plenary // Pléniaire
Plenary Pléniaire // Plenum
Plenum II Free Communications IV Case Presentations
Case Presentations // Cas Cas Cliniques
Cliniques //
Multiple facial
Multiple facial papules:
papules: From
From pimples
pimples
Fallbesprechungen III
Fallbesprechungen III Plenary Lecture VI
to
to cancer
cancer prone
prone
Free Communications / diseases
diseases Plenary / Pléniaire / Plenum V ISDP // SSDV
ISDP SSDV Sessions
Sessions
Clinicopathological aspects of drug
Communications Libres / Freie Cutaneous T cell lymphoma and T
Free
Free Communications
Communications IV
IV eruptions with special emphasis on
Mitteilungen I cell trafficking
biologicals
Plenary Lecture
Plenary Lecture VIVI
Free Communications
Free Communications // Plenary // Pléniaire
Plenary Pléniaire // Plenum
Plenum V V
Clinicopathological aspects
Clinicopathological aspects of of drug
drug
Communications Libres
Communications Libres // Freie
Freie Cutaneous TT cell
Cutaneous cell lymphoma
lymphoma and and TT
eruptions with
eruptions with special
special emphasis
emphasis on on
Mitteilungen II
Mitteilungen cell trafficking
cell
Free Communications trafficking
Plenary / Pléniaire / Plenum II Frontiers in Infectious
biologicals
biologicals
Frontiers in New Entities Communications Libres / Freie
Drug-induced acne Dermatopathology
Organ transplant recipients Mitteilungen III Tropical and subtropical
Follicular pathway to squamous cell
Free Communications
Free Communications dermatopathology
Plenary // Pléniaire
Plenary Pléniaire // Plenum
Plenum IIII carcinoma Frontiers in
Frontiers in Infectious
Infectious
Frontiers in
Frontiers in New
New Entities
Entities Communications
Communications Libres
Libres // Freie
Freie Oncogenic viruses
Drug-induced acne
Drug-induced acne Cutaneous lymphoma update Dermatopathology
Dermatopathology
Case Presentations / Cas Cliniques / Organ transplant
Organ transplant recipients
recipients Mitteilungen
Case PresentationsMitteilungen
/ Cas Cliniques III /
III Molecular techniques in the
Tropical and
Tropical and subtropical
subtropical
Fallbesprechungen I Follicular pathway
Follicular pathway to to squamous
squamous cell cell Fallbesprechungen IV diagnosis of cutaneous infections
dermatopathology
dermatopathology
carcinoma
carcinoma
Oncogenic viruses
Oncogenic viruses
Cutaneous lymphoma
Cutaneous lymphoma update
update
Case Presentations
Case Presentations // Cas
Cas Cliniques
Cliniques // Case Presentations
Case Presentations // Cas Cas Cliniques
Cliniques // Molecular techniques
Molecular techniques in in the
the
Coffee Break Coffee Break diagnosis of
diagnosis of cutaneous
cutaneous infections
infections
Fallbesprechungen II
Fallbesprechungen Fallbesprechungen IV
Fallbesprechungen IV
Exhibition Exhibition
Poster Session Poster Session
Coffee Break
Coffee Break Coffee Break
Coffee Break
Exhibition
Exhibition Exhibition
Exhibition
Plenary / Pléniaire / Plenum III
Poster Session
Poster Session Poster Session
Poster Session
Hemangiomas and vascular Frontiers in Investigative Case Presentations / Cas Cliniques /
malformations: An overview, Dermatopathology Fallbesprechungen V
diagnosis and treatment New molecular targets in skin aging
Plenary // Pléniaire
Plenary Pléniaire // Plenum
Plenum III
III
Dermatopathology at the cutting edge
Hemangiomas and
Hemangiomas and vascular
vascular Frontiers in
Frontiers in Investigative
Investigative Case Presentations
Case Presentations // CasCas Cliniques
Cliniques /Free
/ Communications V
of investigative molecular genetics
malformations: An
malformations: An overview,
overview, Dermatopathology
Dermatopathology Fallbesprechungen V
Fallbesprechungen V
The cutaneous vascular system: a new
diagnosis
diagnosis and
and
Free Communications / treatment
treatment New
New molecular
molecular targets
targets in
in skin
skin aging
aging
Plenary / Pléniaire / Plenum VI
therapeutic target
Communications Libres / Freie Dermatopathology at
Dermatopathology at the
the cutting
cutting edge
edge
Cutaneous vasculitis update: New Free Communications
Free Communications V
V
Mitteilungen II of investigative
of investigative molecular
molecular genetics
geneticsentities, changing paradigms
The cutaneous
The cutaneous vascular
vascular system:
system: aa new
new
Free Communications
Free Communications // therapeutic target
therapeutic target Plenary
Plenary // Pléniaire
Pléniaire // Plenum
Plenum VI
VI
Communications Libres
Communications Libres // Freie
Freie Cutaneous vasculitis
Cutaneous vasculitis update:
update: New
New
Mitteilungen IIII
Mitteilungen Plenary Lecture V entities, changing
entities, changing paradigms
paradigms
Case Presentations / Cas Cliniques / Case Presentations / Cas Cliniques /
Interface dermatitis: The broad
Fallbesprechungen III Fallbesprechungen VI
spectrum of the histological pattern
Plenary Lecture
Plenary Lecture VV Self Assessment Session III (Cases
Meeting / Case Presentations
Case Presentations // Cas
Cas Cliniques
Cliniques // Case Presentations
Case Presentations // Cas
Cas Cliniques
Cliniques //
Interface dermatitis:
Interface dermatitis: The
The broad
broad 21 - 30)
e Infirmières Fallbesprechungen III
Fallbesprechungen III Fallbesprechungen
Fallbesprechungen
Plenary / Pléniaire / Plenum VII VI VI
spectrum of
spectrum of the
the histological
histological pattern
pattern
legefach Mechanisms of melanoma
ruppe metastasis: A historical critique and Self Assessment
Self Assessment Session
Session III
III (Cases
(Cases
Nurse Meeting
Nurse Meeting // new observations 21 -- 30)
21 30)
Séance Infirmières
Séance Infirmières Plenary // Pléniaire
Plenary Pléniaire // Plenum
Plenum VII
VII
// Pflegefach
Pflegefach Mechanisms of
Mechanisms of melanoma
melanoma
Gruppe
Gruppe metastasis: A
metastasis: A historical
historical critique
critique and
and
Concluding Remarks new/ observations
new Conclusions /
observations Concluding Remarks
Schlussfolgerung
Lunch
Satellite Symposia
ISDP Executive Committee Meeting
Exhibition Concluding Remarks
Concluding Remarks // Conclusions
Conclusions //
Concluding Remarks
Concluding Remarks
Poster Session Schlussfolgerung
Schlussfolgerung
Lunch
Lunch
Satellite Symposia
Satellite Symposia
ISDP Executive
ISDP Executive Committee
Committee Meeting
Meeting
Exhibition
Exhibition
Poster Session
Poster Session
Ackerman Lecture (ISDP)
The Large Hadron Collider: Shedding Light on the Dark Universe
Ackerman Lecture
Ackerman Lecture (ISDP)
(ISDP)
The Large
The Large Hadron
Hadron Collider:
Collider: Shedding
Shedding Light
Light on
on the
the Dark
Dark Universe
Universe
Test Yourself - Dermatopathology Quiz (ISDP)
Test Yourself
Test Yourself -- Dermatopathology
Dermatopathology Quiz
Quiz (ISDP)
(ISDP)
Coffee Break
Exhibition
Poster Session
Coffee Break
Coffee Break
Exhibition
Exhibition
Political Seminar / Poster
Poster Session
Session
Self Assessment Session I (Cases
Séminaire Politique /
Berufspolitisches Seminar
1 - 10) PROGRAM Overview
Political Seminar
Political Seminar //
Self Assessment
Self Assessment Session
Session II (Cases
(Cases
Séminaire Politique
Séminaire Politique //
11 -- 10)
10)
SeminarFrontiers in Paradoxal or Provocative
Berufspolitisches Seminar
Berufspolitisches XXXII Symposium de l’International Society of Dermatopathology
Dermatopathology
SSDV General Assembly /
Is keratoacanthoma a squamous cell 93ème Réunion Annuelle de la Société Suisse
carcinoma? Cutaneous neural tumors
SSDV Assemblée Générale / SGDV
Generalversammlung
Frontiers in
Frontiers in Paradoxal
Paradoxal or
with mixed differentiation
Dermatopathology
Dermatopathology
or Provocative
Provocative
de Dermatologie et Vénéréologie
31 Août - 3 Septembre 2011, Genève, Starling Geneva Hotel & Conference Center
Trichoblastic tumors
Is keratoacanthoma
Is keratoacanthoma aa squamous
squamous cellcell
SSDV General
SSDV General Assembly
Assembly // carcinoma? Cutaneous
carcinoma? Cutaneous neural
neural tumors
tumors
SSDV Assemblée
SSDV Assemblée Générale
Générale // SGDV
SGDV with mixed
with mixed differentiation
differentiation
Generalversammlung
Generalversammlung ISDP General Assemblytumors
Trichoblastic
Trichoblastic tumors
XXXII Symposium des International Society of Dermatopathology
ISDP General
ISDP General Assembly
Assembly 93. Jahresversammlung der Schweizerischen
Congress Dinner Gesellschaft für Dermatologie und Venerologie
31. August - 3. September 2011, Genf, Starling Geneva Hotel & Conference Center
Congress Dinner
Congress Dinner
19Sie können auch lesen
